Infectious Disease

Patients in an outpatient oncology unit expressed willingness to receive a pneumococcal or influenza vaccine from a pharmacist if offered.

RSVpreF was well tolerated in nonpregnant and pregnant individuals aged 18 years and older.

The implementation of nonpharmaceutical measures during the COVID-19 pandemic reduced transmission of Streptococcus pneumoniae, a key bacterium that causes pneumococcal disease.

Many adults remain unaware of HPV's cancer risks, highlighting the urgent need for increased awareness.

IDSA updated cUTI guidelines for men and women emphasize antibiotic selection, transition to oral therapy, and optimal treatment duration.

RSV vaccination rates among older adults remain low despite new vaccines, highlighting disparities in uptake and the need for targeted outreach.

Pharmacists play a crucial role in improving vaccination rates among patients with cancer, addressing barriers, and enhancing patient education in oncology care.

In a phase 3 trial, V116 demonstrated significant immunogenicity in older adults who had not before received a pneumococcal vaccination.

RSV poses a serious risk to older adults in long-term care, highlighting the need for effective outbreak management and infection control strategies.

WHO reclassifies hepatitis D as carcinogenic, urging global action to combat viral hepatitis and reduce liver cancer risk.

Continuing a trend observed since the end of the COVID-19 pandemic, vaccine coverage among kindergartners declined in the 2024-2025 school year, according to CDC data.

Ivermectin shows promise in reducing malaria cases, enhancing vector control, and highlighting pharmacists' vital roles in public health strategies.

RSV hospitalization in older adults links to increased cardiovascular events, highlighting the need for vigilant monitoring and vaccination strategies.

RSV outbreaks pose significant risks globally, highlighting the urgent need for targeted vaccination and treatment strategies to protect vulnerable populations.

Cephalosporins are commonly prescribed in the outpatient setting; understanding differences among them is important for pharmacists.

Immense burden is laid upon patients with cancer who are infected with COVID-19, as they are at higher risk of experiencing cancer treatment disruptions and severe illness that necessitates hospitalization.

Immunocompromised patients, especially transplant recipients, face heightened RSV risks, leading to severe infections and complications.

The FDA recently approved gepotidacin oral tablets for the treatment of uncomplicated urinary tract infections (UTIs).

Researchers unveil compounds that enhance cell death and boost antiviral responses, offering hope against RSV and other viral infections.

Funding cuts to public health agencies threaten to worsen chronic diseases and ignite infectious disease outbreaks, straining health care systems nationwide.

Six months following discharge from the hospital, adults who battled community-acquired pneumonia were at heightened risk of losing the ability to perform activities and experiencing poor quality of life.

The injection is indicated for the treatment of sepsis and other serious infections, enhancing treatment efficiency and patient care.

The FDA approves clesrovimab-cfor, a new RSV vaccine, offering infants effective protection against severe respiratory illness during their first RSV season.

CDC urges all US travelers to get vaccinated for measles, mumps, and rubella (MMR) amid rising measles cases, emphasizing prevention as key to combating outbreaks.

Infectious Disease Society of America guidance defines difficult-to-treat resistant Pseudomonas aeruginosa as resistance to all first-line agents.

The FDA approved the MenQuadfi vaccine for young children, enhancing protection against invasive meningococcal disease and its severe complications.

RSV vaccines for pregnant women and infants require careful timing and administration.

Christian John Lillis reflects on key insights from the 2025 Peggy Lillis Foundation C diff Summit, highlighting the critical role of pharmacists in infectious disease care, persistent challenges in patient outcomes, and the need for renewed investment in public health infrastructure and policy.